Canaccord Genuity Maintains Buy on Intra-Cellular Therapies, Raises Price Target to $107
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Sumant Kulkarni has maintained a Buy rating on Intra-Cellular Therapies (NASDAQ:ITCI) and increased the price target from $100 to $107.
April 23, 2024 | 2:49 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Canaccord Genuity maintains a Buy rating on Intra-Cellular Therapies and raises the price target to $107.
The upgrade in the price target by a reputable analyst firm like Canaccord Genuity typically signals a strong conviction in the company's future performance. This can lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100